| Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial A Banerji, MA Riedl, JA Bernstein, M Cicardi, HJ Longhurst, BL Zuraw, ... Jama 320 (20), 2108-2121, 2018 | 253 | 2018 |
| Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial B Zuraw, WR Lumry, DT Johnston, E Aygören-Pürsün, A Banerji, ... Journal of Allergy and Clinical Immunology 148 (1), 164-172. e9, 2021 | 115 | 2021 |
| Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks T Craig, B Zuraw, H Longhurst, M Cicardi, K Bork, C Grattan, C Katelaris, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (6), 1793-1802. e2, 2019 | 81 | 2019 |
| Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks: An Open-Label Extension Study of the COMPACT Trial T Craig, B Zuraw, H Longhurst, M Cicardi, K Bork, C Grattan, C Katelaris, ... | 81* | 2018 |
| Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema WR Lumry, T Craig, B Zuraw, H Longhurst, J Baker, HH Li, JA Bernstein, ... The Journal of Allergy and Clinical Immunology: In Practice 6 (5), 1733-1741. e3, 2018 | 79 | 2018 |
| Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report K Bork, JT Anderson, T Caballero, T Craig, DT Johnston, HH Li, ... Allergy, Asthma & Clinical Immunology 17, 1-14, 2021 | 57 | 2021 |
| Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study A Banerji, JA Bernstein, DT Johnston, WR Lumry, M Magerl, M Maurer, ... Allergy 77 (3), 979-990, 2022 | 48 | 2022 |
| Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled … TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein, H Farkas, WH Yang, ... The Lancet 401 (10382), 1079-1090, 2023 | 39 | 2023 |
| Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks MA Riedl, M Maurer, JA Bernstein, A Banerji, HJ Longhurst, HH Li, P Lu, ... Allergy 75 (11), 2879-2887, 2020 | 39 | 2020 |
| Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study WR Lumry, K Weller, M Magerl, A Banerji, HJ Longhurst, MA Riedl, ... Allergy 76 (4), 1188-1198, 2021 | 37 | 2021 |
| Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study MA Riedl, E Aygören‐Pürsün, J Baker, H Farkas, J Anderson, ... Allergy 73 (9), 1871-1880, 2018 | 37 | 2018 |
| Subsets of airway myeloid-derived regulatory cells distinguish mild asthma from chronic obstructive pulmonary disease JS Deshane, DT Redden, M Zeng, ML Spell, JW Zmijewski, JT Anderson, ... Journal of Allergy and Clinical Immunology 135 (2), 413-424. e15, 2015 | 29 | 2015 |
| Elevated levels of NO are localized to distal airways in asthma JT Anderson, M Zeng, Q Li, R Stapley, DR Moore II, B Chenna, ... Free Radical Biology and Medicine 50 (11), 1679-1688, 2011 | 28 | 2011 |
| Optimal management of hereditary angioedema: shared decision-making A Banerji, J Anderson, DT Johnston Journal of asthma and allergy, 119-125, 2021 | 22 | 2021 |
| Health-related quality of life in primary immunodeficiencies: impact of delayed diagnosis and treatment burden JT Anderson, J Cowan, A Condino-Neto, D Levy, S Prusty Clinical Immunology 236, 108931, 2022 | 21 | 2022 |
| Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings … WR Lumry, B Zuraw, M Cicardi, T Craig, J Anderson, A Banerji, ... Orphanet journal of rare diseases 16 (1), 1-14, 2021 | 19 | 2021 |
| Hereditary angioedema: Comprehensive management plans and patient support. D Paige, N Maina, JT Anderson Allergy & Asthma Proceedings 41, 2020 | 17 | 2020 |
| Androgen use in hereditary angioedema: a critical appraisal and approaches to transitioning from androgens to other therapies DT Johnston, H Henry Li, TJ Craig, JA Bernstein, J Anderson, K Joseph, ... Allergy and Asthma Proceedings 42 (1), 22-29, 2021 | 15 | 2021 |
| Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings T Craig, W Lumry, M Cicardi, B Zuraw, JA Bernstein, J Anderson, J Jacobs, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (6), 2035-2038, 2019 | 14 | 2019 |
| Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema D Levy, T Caballero, I Hussain, A Reshef, J Anderson, J Baker, ... Pediatric Allergy, Immunology, and Pulmonology 33 (3), 136-141, 2020 | 12 | 2020 |
Teresa CaballeroAllergy Department, Hospital Universitario La Paz, IdiPaz, CIBERER, Madrid, Spain在 idipaz.es 的电子邮件经过验证
